Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Go back to Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial| (NASDAQ: ADAP) | Delayed: 0.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.05 | 52 Week High | $12.85 | |||
| Open | $0.05 | 52 Week Low | $3.76 | |||
| Day High | $0.05 | P/E | N/A | |||
| Day Low | $0.05 | EPS | $0.00 | |||
| Volume | 1,244,611 | |||||
